{"protocolSection": {"identificationModule": {"nctId": "NCT01935622", "orgStudyIdInfo": {"id": "VCU HM14393"}, "organization": {"fullName": "Virginia Commonwealth University", "class": "OTHER"}, "briefTitle": "Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy", "officialTitle": "Phase II Study of Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy", "acronym": "DOXY-HF"}, "statusModule": {"statusVerifiedDate": "2014-08", "overallStatus": "TERMINATED", "whyStopped": "End of funding", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-07"}, "primaryCompletionDateStruct": {"date": "2014-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-08-23", "studyFirstSubmitQcDate": "2013-09-04", "studyFirstPostDateStruct": {"date": "2013-09-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-06-20", "resultsFirstSubmitQcDate": "2014-08-19", "resultsFirstPostDateStruct": {"date": "2014-08-20", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-08-19", "lastUpdatePostDateStruct": {"date": "2014-08-20", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Virginia Commonwealth University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Non-ischemic cardiomyopathy and heart failure are highly influenced by the presence of systemic inflammation.\n\nDoxycycline is a FDA-approved drug to treat bacterial infections which also shows powerful anti-inflammatory effects.\n\nIn this study we plan to determine the effects of Doxycycline in patients with stable heart failure and non-ischemic cardiomyopathy on peak of aerobic exercise capacity (peak V02) and ventilator efficiency measured with a cardiopulmonary test.", "detailedDescription": "In this study of Safety and Efficacy of Doxycycline in Patients with Non-Ischemic Cardiomyopathy Population, we will enroll 24 patients with a clinical diagnosis of heart failure and non-ischemic cardiomyopathy (recent imaging study documenting LV ejection fraction \\<50%, and no history of coronary or ischemic heart disease) in a single-center, randomized, double-blinded, placebo-controlled clinical trial with allocation 1:1:1 to Doxycycline 100 mg twice daily or Doxycycline 20 mg twice daily or Placebo for 2 weeks."}, "conditionsModule": {"conditions": ["Non-ischemic Cardiomyopathy", "Systolic Heart Failure (NYHA II-III)"], "keywords": ["heart failure", "non-ischemic cardiomyopathy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 10, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Doxycycline 100 mg", "type": "EXPERIMENTAL", "description": "Doxycycline 100 mg twice daily for 14 days", "interventionNames": ["Drug: Doxycycline"]}, {"label": "Doxycycline 20 mg", "type": "EXPERIMENTAL", "description": "Doxycycline 20 mg twice daily for 14 days", "interventionNames": ["Drug: Doxycycline"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: placebo"]}], "interventions": [{"type": "DRUG", "name": "Doxycycline", "description": "Doxycycline 1 tablet every 12 hours for 14 days", "armGroupLabels": ["Doxycycline 100 mg", "Doxycycline 20 mg"]}, {"type": "DRUG", "name": "placebo", "description": "Placebo 1 tablet every 12 hours for 14 days", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Peak Aerobic Exercise Capacity", "description": "Interval change in peak VO2 measured at cardiopulmonary test", "timeFrame": "14 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Non-ischemic cardiomyopathy (LVEF\\<40%)\n* Heart failure NYHA II-III\n\nExclusion Criteria:\n\n* Age \\<18\n* Recent changes (previous 3 months) in HF maintenance medications (beta-blockers, angiotensin converting enzyme \\[ACE\\] inhibitors, aldosterone antagonists, vasodilators, cardiac glycosides, diuretics)\n* Hospitalization for worsening HF or acute decompensated HF within the previous 12 months\n* History of coronary or ischemic heart disease\n* Anticipated need for cardiac resynchronization therapy (CRT) or automated-implantable cardioverter defibrillator (AICD) or coronary revascularization or cardiac surgery\n* Angina or electrocardiograph (ECG) changes that limit maximum exertion during cardiopulmonary exercise testing\n* Active infection including chronic infection\n* Active cancer (or prior diagnosis of cancer within the past 10 years)\n* Recent (\\<14 days) use of anti-inflammatory drugs (not including NSAIDs), Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus), malignancy, or any comorbidity limiting survival or ability to complete the study\n* Pregnancy\n* Inability to give informed consent\n* Other conditions limiting completion of cardiopulmonary exercise test or completion of the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Antonio Abbate, M.D.", "affiliation": "Virginia Commonwealth University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Virginia Commonwealth University", "city": "Richmond", "state": "Virginia", "zip": "23298", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Doxycycline 100 mg", "description": "Doxycycline 100 mg twice daily for 14 days\n\nDoxycycline"}, {"id": "FG001", "title": "Doxycycline 20 mg", "description": "Doxycycline 20 mg twice daily for 14 days\n\nDoxycycline"}, {"id": "FG002", "title": "Placebo", "description": "Placebo\n\nplacebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "(No data analysis conducted. Insufficient enrollment)", "groups": [{"id": "BG000", "title": "Doxycycline 100 mg", "description": "Doxycycline 100 mg twice daily for 14 days\n\nDoxycycline"}, {"id": "BG001", "title": "Doxycycline 20 mg", "description": "Doxycycline 20 mg twice daily for 14 days\n\nDoxycycline"}, {"id": "BG002", "title": "Placebo", "description": "Placebo\n\nplacebo"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "10"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52", "lowerLimit": "48", "upperLimit": "55"}, {"groupId": "BG001", "value": "58", "lowerLimit": "55", "upperLimit": "59"}, {"groupId": "BG002", "value": "54", "lowerLimit": "49", "upperLimit": "60"}, {"groupId": "BG003", "value": "54", "lowerLimit": "48", "upperLimit": "60"}]}]}]}, {"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "10"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "2"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "8"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "10"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Peak Aerobic Exercise Capacity", "description": "Interval change in peak VO2 measured at cardiopulmonary test", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "timeFrame": "14 days", "groups": [{"id": "OG000", "title": "Doxycycline 100 mg", "description": "Doxycycline 100 mg twice daily for 14 days\n\nDoxycycline"}, {"id": "OG001", "title": "Doxycycline 20 mg", "description": "Doxycycline 20 mg twice daily for 14 days\n\nDoxycycline"}, {"id": "OG002", "title": "Placebo", "description": "Placebo\n\nplacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "(No data analysis conducted. Insufficient enrollment)"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "(No data analysis conducted. Insufficient enrollment)"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "(No data analysis conducted. Insufficient enrollment)"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Doxycycline 100 mg", "description": "Doxycycline 100 mg twice daily for 14 days\n\nDoxycycline", "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 0, "otherNumAtRisk": 3}, {"id": "EG001", "title": "Doxycycline 20 mg", "description": "Doxycycline 20 mg twice daily for 14 days\n\nDoxycycline", "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 1, "otherNumAtRisk": 3}, {"id": "EG002", "title": "Placebo", "description": "Placebo\n\nplacebo", "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 0, "otherNumAtRisk": 4}], "otherEvents": [{"term": "Hypotension", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "(No data analysis conducted. Insufficient enrollment)"}, "certainAgreement": {"piSponsorEmployee": true, "restrictiveAgreement": false}, "pointOfContact": {"title": "Antonio Abbate", "organization": "Virginia Commonwealth University", "email": "aabbate@vcu.edu", "phone": "8048280513"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000009202", "term": "Cardiomyopathies"}, {"id": "D000054143", "term": "Heart Failure, Systolic"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M27579", "name": "Heart Failure, Systolic", "asFound": "Systolic Heart Failure", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000004318", "term": "Doxycycline"}], "ancestors": [{"id": "D000000900", "term": "Anti-Bacterial Agents"}, {"id": "D000000890", "term": "Anti-Infective Agents"}, {"id": "D000000962", "term": "Antimalarials"}, {"id": "D000000981", "term": "Antiprotozoal Agents"}, {"id": "D000000977", "term": "Antiparasitic Agents"}], "browseLeaves": [{"id": "M7493", "name": "Doxycycline", "asFound": "Resources", "relevance": "HIGH"}, {"id": "M4222", "name": "Anti-Bacterial Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}, {"id": "M4280", "name": "Antimalarials", "relevance": "LOW"}, {"id": "M4298", "name": "Antiprotozoal Agents", "relevance": "LOW"}, {"id": "M4294", "name": "Antiparasitic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}